FDA accepts NRx's ANDA for preservative-free IV ketamine KETAFREE with July 2026 goal date

NRx Pharmaceuticals, Inc. (NRXP) — NRx Pharmaceuticals said the FDA received and deemed substantially complete its Abbreviated New Drug Application for KETAFREE, a single-patient, preservative-free IV ketamine formulation, assigning a July 29, 2026 review goal date.

KETAFREE is positioned as an alternative to multidose ketamine vials containing benzethonium chloride, and the filing advances NRx's broader ketamine franchise, which also includes NRX-100 for suicidal depression.

Source: ir.nrxpharma.com

For the rest of that week's sector news, read our week in review.